Related references
Note: Only part of the references are listed.Outcomes of adults with active or progressive hematological malignancies at the time of allo-SCT: a survey from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC)
P. Chevallier et al.
BONE MARROW TRANSPLANTATION (2014)
Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab
Patrick Schlegel et al.
HAEMATOLOGICA (2014)
Long-term follow-up of serum immunoglobulin levels in blinatumomab-treated patients with minimal residual disease-positive B-precursor acute lymphoblastic leukemia
G. Zugmaier et al.
BLOOD CANCER JOURNAL (2014)
Blinatumomab induces autologous T-cell killing of chronic lymphocytic leukemia cells
Ryan Wong et al.
HAEMATOLOGICA (2013)
Sorafenib in patients with refractory or recurrent multiple myeloma
Anna Yordanova et al.
HEMATOLOGICAL ONCOLOGY (2013)
Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab
Matthias Klinger et al.
BLOOD (2012)
Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL
Max S. Topp et al.
BLOOD (2012)
Targeted Therapy With the T-Cell-Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival
Max S. Topp et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Combination of rituximab with blinatumomab (MT103/MEDI-538), a T cell-engaging CD19-/CD3-bispecific antibody, for highly efficient lysis of human B lymphoma cells
Sandrine d'Argouges et al.
LEUKEMIA RESEARCH (2009)
Share Paper
